Linzagolix 是一种口服有活性的非多肽GnRH拮抗剂。可用于研究子宫肌瘤、子宫腺肌症、子宫内膜异位症。

Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.

935283-04-8

C22H15F3N2O7S

508.42

DMSO:55 mg/ml (108.18 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years